De Novo Focal Segmental Glomerulosclerosis (FSGS) Post Covid 19 Vaccination: Case Series in A Single Centre in Malaysia
https://doi.org/10.47836/mjmhs.19.6.47
- Author:
Jonathan Thian Hooi Yong
1
;
Xun Quan Sze
1
;
Christopher Thiam Seong Lim
2
;
Bak Leong Goh
1
,
3
Author Information
1. Department of Medicine, Sultan Idris Shah Hospital, Jalan Puchong, 43000 Kajang, Selangor Malaysia&
2. Nephrology Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia
3. Clinical Research Centre, Sultan Idris Shah Hospital, Jalan Puchong, 43000 Kajang, Selangor Malaysia
- Publication Type:Other Types
- Keywords:
COVID-19, vaccination, focal segmental glomerulosclerosis (FSGS), kidney biopsy
- From:Malaysian Journal of Medicine and Health Sciences
2023;19(No.6):360-363
- CountryMalaysia
- Language:English
-
Abstract:
Introduction: Mass COVID-19 vaccination has been pivotal in the fight against this pandemic. The occurrence of
glomerular disease following COVID-19 vaccinations particularly mRNA vaccine has been reported. The reported
cases in the region are limited and number of cases reported are low in contrast to the total number of vaccine doses
given worldwide, the healthcare providers should be alerted about such issues to provide swift and proper management. Case Series: Here, we report 3 cases of Focal segmental glomerulosclerosis (FSGS) following COVID-19 vaccination and their outcomes. Two of the patients received BNT162b2 vaccination and one received CoronaVac vaccination. The mean age of the patients was 33+/-7 years old. The mean duration onset of FSGS was 23+/-19 days post
vaccinations. Two of the patients (BNT162b2 vaccination and CoronaVac vaccination) achieved complete remission
after corticosteroid therapy. This is the first reported case of De Novo FSGS following CoronaVac vaccination in the
literature. The third patient, who received BNT162b2 vaccination and presented late (42 days post vaccination) was
not in remission despite three months of immunosuppressive treatment. Conclusion: The treating physician needs to
be aware of the possibility of the development of FSGS associated with COVID-19 vaccination and how to proceed
with vaccination schedule in these populations. Overall, the advantage of COVID-19 vaccination far outweighs the
possibility of COVID-19 vaccine-associated glomerular disease.
- Full text:11.2023my1701.pdf
